Skip to content

Services
Study Designer
Resources
Insights & Case Studies
- Case Studies
- Insights

Services
Study Designer
Resources
Insights & Case Studies
- Case Studies
- Insights

Inovia Bio Insights

Keep Up To Date With All Things Inovia Bio &
Drug Development

Twelve-point external control arm design checklist for FDA and EMA regulatory submissions

RWEStrategyReal world evidenceexternal control armsregulatory strategy

The external control arm design checklist: 12 points that survive scrutiny

Inovia Bio featured image for the evidence gap audit: five axes for grading regulatory readiness in a drug development programme before FDA or EMA review.

StrategyIEPdrug development

The evidence gap audit: five axes to grade your programme before a reviewer does

RWEStrategyReal world evidencedrug development

Coordination Without Consensus: Why Your Functions Tell Four Different Stories About The Same Evidence

Atlas comparing real-world data source selection across claims, EHR, registries and wearables for regulatory-grade evidence

RWEStrategyReal world evidence

The RWD source atlas: choose your data source by its blind spot, not its brochure

Real-world evidence glossary comparing how regulators, payers and CROs define RWE and RWD terms differently

RWEReal world evidence

The RWE glossary: the terms your regulator, payer and CRO define differently (and the ones they don't)

A lifecycle map of real-world evidence in drug development, from disease sizing at discovery to label expansion after launch.

RWEReal world evidenceHTAdrug development

The real-world evidence map: every entry point in a drug programme, and why the best ones come early

Inovia Bio insight on regulatory-grade real-world data and the reconstruction test for RWD reliability, provenance and traceability.

RWEReal world evidence

What 'regulatory grade' actually requires: the reconstruction test your real-world data has to survive

Inovia Bio graphic on primary vs supportive real-world evidence roles in FDA regulatory submissions

RWEStrategyIEPReal world evidencedrug development

Primary vs supportive RWE: decide the role before you design the study

External control arm causal inference: the exchangeability, positivity and consistency conditions that stand in for randomisation

RWEReal world evidencedrug development

Randomisation has exactly one job. An external control arm has to do it by hand.

Inovia Bio case study on external control arm acceptance: blinatumomab's FDA and EMA regulatory pathway from single-arm trial to confirmatory randomised trial.

StrategyReal world evidenceexternal control armsregulatory strategy

The external control arm that got checked against reality: what blinatumomab's acceptance actually required

Previous page 1...3 4 5...9 Next page

Privacy Policy · © 2025. All rights reserved.